-
Journal of the American Animal Hospital... 2011This study reports the outcomes of dogs with grade 3 mast cell tumors (MCTs). Clinical and histopathological data were available for 43 dogs. Median progression-free...
This study reports the outcomes of dogs with grade 3 mast cell tumors (MCTs). Clinical and histopathological data were available for 43 dogs. Median progression-free survival (PFS) and overall survival (OS) were 133 and 257 days, respectively. Tumor size, lymph node (LN) status, and mitotic index (MI) significantly influenced PFS in univariate analysis. Tumor size and LN status remained significant in the multivariate analysis. Lymph node status, local tumor control, LN treatment, and MI significantly influenced OS in univariate analysis but only LN status remained significant in multivariate analysis. These results confirm that locoregional control improves outcomes in patients with grade 3 MCTs.
Topics: Animals; Disease-Free Survival; Dog Diseases; Dogs; Female; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Mast-Cell Sarcoma; Mitotic Index; Multivariate Analysis; Neoplasm Staging; Retrospective Studies; Treatment Outcome
PubMed: 21164163
DOI: 10.5326/JAAHA-MS-5557 -
Brief communication, Histopathology of a spontaneously developing mast cell sarcoma in a Wistar rat.Toxicologic Pathology 1996A case report is given of a very rare spontaneous mast cell tumor in the eyelid of the left eye of a female Wistar rat used in a long-term oral toxicity study....
A case report is given of a very rare spontaneous mast cell tumor in the eyelid of the left eye of a female Wistar rat used in a long-term oral toxicity study. Metastasis of the tumor had occurred in the mandibular lymph nodes and in the liver. Clinically, the animal showed blepharospasm, dacryorrhoea, and exophthalmus. Hematologic findings included slight eosinophilia and a remarkable basophilia. At necropsy, a bilateral conjunctivitis was diagnosed and a tumorous mass was found in the left submandibular region. Histologically, the tumor was composed of round to polygonal cells with pale cytoplasm, containing abundant predominantly basophilic granules. The intracytoplasmatic granules stained metachromatically with Toluidine blue and immunostained positively with serotonin. Numerous eosinophils were scattered throughout the tumor and were also present in other organs. Cells with round, oval, or indented nuclei and abundant cytoplasm, containing pronounced eosinophilic granules, were found in spleen and bone marrow. They turned out to be immature stages of eosinophilic granulocytes. Characteristics of the present tumor are compared with observations on mast cell tumors in other species.
Topics: Animals; Eye; Eyelid Neoplasms; Female; Leukocyte Count; Liver Neoplasms; Lymphatic Metastasis; Mast-Cell Sarcoma; Rats; Rats, Wistar; Rodent Diseases
PubMed: 8736393
DOI: 10.1177/019262339602400313 -
Journal of the American Veterinary... Jan 2000To characterize the clinical features of visceral mast cell tumors (MCT) without associated cutaneous involvement in dogs.
OBJECTIVE
To characterize the clinical features of visceral mast cell tumors (MCT) without associated cutaneous involvement in dogs.
DESIGN
Retrospective study.
ANIMALS
10 dogs with histologically confirmed MCT without associated cutaneous lesions.
PROCEDURE
Information on signalment, clinical signs, laboratory examinations, and time from first admission to death was obtained from the medical record of each dog.
RESULTS
Purebred male dogs of miniature breeds appeared to have a higher prevalence of visceral MCT. Clinical signs included anorexia, lethargy, vomiting, and diarrhea. Anemia (n = 7), hypoproteinemia (5), and mastocythemia (5) were detected. Treatments, including glucocorticoids, were not successful. Primary sites of tumors were the gastrointestinal tract (n = 6) and the spleen or liver (1); the primary site was not confirmed in the remaining 3 dogs. In 7 dogs, tumors were categorized as grade II or III, on the basis of histologic findings. The prognoses were poor, and all dogs died within 2 months after first admission.
CONCLUSIONS AND CLINICAL RELEVANCE
Visceral MCT is uncommon in dogs, and the prognosis is extremely poor. Biological behavior and drug susceptibility of visceral MCT may be different from cutaneous MCT. The lack of specific clinical signs may result in delay of a definitive diagnosis. The rapid progression of clinical signs and difficulty in diagnosis contributes to a short survival time.
Topics: Animals; Blood Cell Count; Blood Chemical Analysis; Breeding; Dog Diseases; Dogs; Female; Intestinal Neoplasms; Liver Neoplasms; Male; Mast-Cell Sarcoma; Prognosis; Retrospective Studies; Splenic Neoplasms
PubMed: 10649758
DOI: 10.2460/javma.2000.216.222 -
Journal of the National Cancer Institute Sep 1979Twenty-three dogs completed a fractionated course of ionizing radiation therapy for mast cell tumors. In 10 dogs the response was satisfactory, and the tumors were...
Twenty-three dogs completed a fractionated course of ionizing radiation therapy for mast cell tumors. In 10 dogs the response was satisfactory, and the tumors were considered controlled 12 months after completion of the prescribed course of therapy. Treatment was considered unsatisfactory for the remaining 13 dogs due to failure to control the tumor locally, generalized metastasis, or both. A dose effect was noted in the response of the tumors to radiation. Of 6 dogs, 5 responded satisfactorily when the tumor dose was 4,000 rads or greater. When the tumor dose was less than 4,000 rads, 5 of 17 dogs responded satisfactorily. The dose calculated to control 50% of the meat cell tumors was 3,625 rads (95% confidence interval: 3,265-4,024 rads). Adverse normal tissue reactions, which consisted of moist desquamation in 10 animals and necrosis in 4, were recorded. The dose calculated to cause desquamation in 50% of the dogs was 3,750 rads (95% confidence interval: 3,348-4,200 rads).
Topics: Animals; Dog Diseases; Dogs; Dose-Response Relationship, Radiation; Female; Male; Mast-Cell Sarcoma; Radioisotope Teletherapy; Skin Neoplasms
PubMed: 112313
DOI: 10.1093/jnci/63.3.691 -
Veterinary and Comparative Oncology Jun 2009The purpose of this retrospective cohort study is to describe the association of cytological assessment of lymph node metastasis with survival and tumour grade in dogs...
The purpose of this retrospective cohort study is to describe the association of cytological assessment of lymph node metastasis with survival and tumour grade in dogs with mast cell tumours. Regional lymph node aspirates of 152 dogs diagnosed with a mast cell tumour were reviewed and classified according to specific cytological criteria for staging. 97 dogs (63.8%) had stage I tumours, and 55 (36.2%) had stage II tumours. Stage II dogs had a significantly shorter survival time than dogs with stage I disease (0.8 and 6.2 years, respectively; P < 0.0001). Dogs with grade III mast cell tumours were more likely to have stage II disease (P = 0.004). These results suggest that cytological evaluation of lymph nodes in dogs with mast cell tumours provides useful and valuable clinical information, and the results correlate with tumour grade and outcome thus providing a practical and non-invasive method for staging.
Topics: Animals; Cohort Studies; Dog Diseases; Dogs; Female; Lymph Nodes; Lymphatic Metastasis; Male; Mast-Cell Sarcoma; Neoplasm Staging; Retrospective Studies; Sentinel Lymph Node Biopsy; Survival Analysis
PubMed: 19453367
DOI: 10.1111/j.1476-5829.2009.00185.x -
HNO Jun 1994
Review
Topics: Humans; Mast Cells; Mast-Cell Sarcoma; Mastocytosis; Microscopy, Electron; Skin; Urticaria Pigmentosa
PubMed: 8071100
DOI: No ID Found -
Veterinary Radiology & Ultrasound : the... 1998The records of 56 dogs treated with megavoltage radiation for mast cell neoplasia were reviewed to determine the efficacy of this treatment modality. Total radiation... (Comparative Study)
Comparative Study
The records of 56 dogs treated with megavoltage radiation for mast cell neoplasia were reviewed to determine the efficacy of this treatment modality. Total radiation dose ranged from 45 to 57 Gray (Gy), dose per fraction ranged from 3.0 to 4.0 Gy, and radiation treatment time ranged from 14-28 days. Median disease free interval (95% CI) was 32.7 (19-70) months. Median disease free interval for dogs older than 7.5 years was 15 (lower limit 7) months as compared to 62 (lower limit 20) for dogs younger than 7.5 years of age (p = 0.006). Median disease free interval for dogs with measurable disease was 12 (lower limit 5) months as compared to 54 (32-70) months for dogs with microscopic disease (p = 0.006). Radiation treatment time was also significantly related to disease free interval. Median disease free interval for dogs treated longer than 22 days was 12 (7-19) months as compared to greater than 50 (lower limit 20) months for dogs treated in 22 or fewer days (p < 0.001). This appeared to be due to more recurrences in dogs treated with 3-per-week fractionation and suggests that tumor proliferation in the interfraction interval may be important. Sex, tumor location, histologic grade, WHO clinical stage, number of radiation fractions, total radiation dose, and dose-per-fraction, as well as the following "yes/no" variables: steroids given, surgery prior to radiation, lymph nodes irradiated, and development of another mast cell tumor did not appear to influence median disease free interval or survival. Data presented herein support megavoltage radiation as an effective treatment for canine mast cell neoplasia, and suggest that disease free interval in dogs treated with daily fractions may be longer than that achieved with alternating day fractions.
Topics: Adrenal Cortex Hormones; Age Factors; Animals; Cobalt Radioisotopes; Disease-Free Survival; Dog Diseases; Dogs; Dose Fractionation, Radiation; Female; Follow-Up Studies; Lymph Nodes; Lymphatic Metastasis; Male; Mast-Cell Sarcoma; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Second Primary; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, High-Energy; Retrospective Studies; Sex Factors; Skin Neoplasms; Survival Rate; Time Factors
PubMed: 9491519
DOI: 10.1111/j.1740-8261.1998.tb00326.x -
Histopathology Sep 1979
Topics: Adult; Aged; Animals; Child; Female; Humans; Leukemia; Male; Mast Cells; Mast-Cell Sarcoma; Middle Aged; Urticaria Pigmentosa
PubMed: 114472
DOI: 10.1111/j.1365-2559.1979.tb03017.x -
Journal of the American Veterinary... Apr 2001To determine outcome for dogs with grade-II mast cell tumors treated with surgery alone.
OBJECTIVE
To determine outcome for dogs with grade-II mast cell tumors treated with surgery alone.
DESIGN
Retrospective study.
ANIMALS
55 dogs.
PROCEDURES
Medical records were examined, and signalment; location and size of tumor; staging status; dates of local recurrence, metastasis, death, or last follow-up examination; status of surgical margins; previous surgery; postoperative complications; and cause of death were recorded. Follow-up information was obtained via reexamination or telephone conversations with owners or referring veterinarians. Univariate analysis was performed to identify prognostic factors.
RESULTS
60 tumors in 55 dogs were included. Median follow-up time was 540 days. Three (5%) mast cell tumors recurred locally; median time to local recurrence was 62 days. Six (11%) dogs developed another mast cell tumor at a different cutaneous location; median time to a different location was 240 days. Three (5%) dogs developed metastases; median time to metastasis was 158 days. Fourteen dogs died; 3 deaths were related to mast cell tumor, and 7 were unrelated. The relationship with mast cell tumor was not known for 4. Median survival times were 151, 841, and 827 days, respectively, for these 3 groups. Forty-six (84%) dogs were free of mast cell tumors during the study period. A reliable prognostic factor could not be identified.
CONCLUSIONS AND CLINICAL RELEVANCE
Results suggest that additional local treatment may not be required after complete excision of grade-II mast cell tumors and that most dogs do not require systemic treatment.
Topics: Animals; Dog Diseases; Dogs; Female; Follow-Up Studies; Male; Mast-Cell Sarcoma; Neoplasm Recurrence, Local; Retrospective Studies; Skin Neoplasms; Survival Analysis; Treatment Outcome
PubMed: 11318363
DOI: 10.2460/javma.2001.218.1120 -
BMC Veterinary Research Jan 2020Traditionally, wide lateral surgical margins of 3 cm and one fascial plane deep have been recommended for resection of canine cutaneous mast cell tumor (MCT). Several...
BACKGROUND
Traditionally, wide lateral surgical margins of 3 cm and one fascial plane deep have been recommended for resection of canine cutaneous mast cell tumor (MCT). Several studies have been published assessing surgical margins of less than this traditional recommendation. The objective of this systematic review was to determine if resection MCT with lateral surgical margins < 3 cm results in low rates of incomplete resection and local tumor recurrence. Systematic searches of digital bibliographic databases were performed with two authors (AR & LES) screening abstracts to identify relevant scientific articles. Studies regarding surgical treatment of dogs with cutaneous MCT were reviewed. Data abstraction was performed and the quality of individual studies and the strength of the body of evidence for utilization of surgical margins < 3 cm for removal of MCTs was assessed.
RESULTS
From the initial 78 citations identified through the database searches, four articles were retained for data abstraction after both relevance screenings were performed. Two studies were retrospective observational studies, one was a prospective case series and one was a prospective clinical trial. Assessment of the quality level of the body of evidence identified using the GRADE system was low. Excision of MCT at 2 cm and 3 cm was associated with comparably low rates of incomplete excision and recurrence.
CONCLUSIONS
Despite the low quality of the overall body of evidence, a recommendation can be made that resection of canine cutaneous MCTs (< 4 cm) of Patnaik grade I and II with 2 cm lateral margins and 1 fascial plane deep results in low rates of incomplete excision and local tumor recurrence.
Topics: Animals; Dog Diseases; Dogs; Margins of Excision; Mast-Cell Sarcoma; Neoplasm Recurrence, Local; Skin Neoplasms; Treatment Outcome
PubMed: 31906934
DOI: 10.1186/s12917-019-2227-8